|
|
Quince Therapeutics Shares Resume Trade
|
|
|
|
Trading Halt: Halt status updated at 3:25:00 PM ET: Quotation Resumption: News and Resumption Times
|
|
|
|
Quince Therapeutics Announces Its Phase 3 NEAT Clinical Study Of Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes Failed To Meet Statistical Significance And Key Secondary Endpoint Of Improvement In Clinical Global Impression Of Severity
|
|
|
|
Trading Halt: Halted at 3:06:46 p.m. ET - Trading Halt: Halt News Pending
|
|
|
|
D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $5 Price Target
|
|
|
|
Quince Therapeutics Announced The Poster Presentation From The Long-term Treatment Of Children With Ataxia-Telangiectasia At The British Paediatric Neurology Association 2026 Annual Meeting; Long-term Treatment With eDSP In Children With A-T Was Associated With Stable Growth And Metabolic Parameters Without Indications Of Corticosteroid-Related Toxicities
|
|
|
|
Quince Therapeutics Option Alert: Mar 20 $7.5 Calls Sweep (7) Near The Ask: 1417 @ $0.739 Vs 2841 OI; Ref=$2.87
|
|